KYNTRA BIO, INC.

For the period ended Dec 31, 2024. Filed Mar 17, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Mar 17, 2025

KYNB$3.90+4.6%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Operations

(In thousands, except per share amounts)

	Years Ended December 31,
	2024	2023
Revenue:
License revenue	$—	$9,649
Development and other revenue	1,948	18,401
Drug product revenue, net	27,673	18,753
Total revenue	29,621	46,803
Operating costs and expenses:
Cost of goods sold	15,561	3,962
Research and development	95,692	266,473
Selling, general and administrative	49,330	86,483
Restructuring charge	19,454	12,606
Total operating costs and expenses	180,037	369,524
Loss from operations	(150,416)	(322,721)
Interest and other, net
Interest expense	(8,247)	(8,095)
Interest income and other income (expenses), net	5,296	7,594
Total interest and other, net	(2,951)	(501)
Loss from continuing operations before income taxes	(153,367)	(323,222)
Benefit from income taxes	(269)	(252)
Loss from continuing operations	(153,098)	(322,970)
Income from discontinued operations, net of tax	105,519	38,738
Net loss	$(47,579)	$(284,232)
Loss from continuing operations per share - basic and diluted	$(1.53)	$(3.32)
Income from discontinued operations per share - basic and diluted	1.05	$0.40
Net loss per share - basic and diluted	$(0.48)	$(2.92)
Weighted average number of common shares used to calculate net loss per share - basic and diluted	100,044	97,303

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.